Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia.

ABSTRACT:

Introduction and objectives

Tocilizumab is an interleukin-6 receptor-blocking agent proposed for the treatment of severe COVID-19; however, limited data are available on their efficacy. The aim of this study was to assess the effect of tocilizumab on the outcomes of patients with COVID-19 pneumonia by using propensity-score-matching (PSM) analysis.

Methods

A retrospective observational analysis of hospitalized COVID-19 adult patients admitted to the Vall d'Hebron Hospital was performed between March and April 2020. We used the logistic regression to analyze the effect of tocilizumab on mortality, as main outcome, and PSM analysis to further validate their effect. Secondary outcomes were length-of-stay (LOS) and intensive-care-unit (ICU) stay. Same outcomes were also assessed

SUBMITTER: Cardona-Pascual I 

PROVIDER: S-EPMC9063125 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature